GT Metabolic Solutions Announces Series C Growth Investment Led by J.P. Morgan Life Sciences Private Capital
Financial Post ·
MINNEAPOLIS -- GT Metabolic ™ Solutions, Inc. (“the Company” or “GT Metabolic”), a pioneer in the medical device field and the first to receive FDA De Novo grant and 510(k) clearance for use of magnetic technology to create compression anastomoses (connections between two tubular structures in the body, such as intestines), today announced a Series C growth investment from J.P. Morgan Life Sciences Private Capital. Proceeds from the financing will support the Company’s ongoing global commercial launch and fund expansion into new surgical and therapeutic settings, with endoscopic and colorectal surgery next with additional indications to follow. Read More